ANTI-TRANSFORMING GROWTH FACTOR-β GENE THERAPY
作者： Wayne A. Border
DOI:
关键词:
摘要: The present invention provides methods for reducing a pathology in subject characterized by deleterious accumulation of TGF-β-induced extracellular matrix tissue introducing nucleic acid encoding TGFβ-specific inhibitory agent or active fragment thereof into cell the subject. In one embodiment, TGF-β specific is introduced vivo injection, example, skeletal muscle. another transfected ex to obtain expressing agent, and then administered be treated. agents include, but are not limited to, members decoring family proteoglycans such as decorin, biglycan, fibromodulin lumican an antibody TGF-β. Pathologies that can reduced include various fibrotic diseases conditions.
lens.org 参考文章(34)
Joan Massagué, Purified proteoglycan betaglycan, compositions, and methods ,(1992)
T.C. Blochberger, P.K. Cornuet, J.R. Hassell, Isolation and partial characterization of lumican and decorin from adult chicken corneas. A keratan sulfate-containing isoform of decorin is developmentally regulated. Journal of Biological Chemistry. ,vol. 267, pp. 20613- 20619 ,(1992) , 10.1016/S0021-9258(19)36731-6
D Fukushima, R Bützow, A Hildebrand, E Ruoslahti, Localization of transforming growth factor beta binding site in betaglycan. Comparison with small extracellular matrix proteoglycans. Journal of Biological Chemistry. ,vol. 268, pp. 22710- 22715 ,(1993) , 10.1016/S0021-9258(18)41585-2
K Kato, M Nakanishi, Y Kaneda, T Uchida, Y Okada, Expression of hepatitis B virus surface antigen in adult rat liver. Co-introduction of DNA and nuclear protein by a simplified liposome method. Journal of Biological Chemistry. ,vol. 266, pp. 3361- 3364 ,(1991) , 10.1016/S0021-9258(19)67798-7
V.M. Kähäri, H. Larjava, J. Uitto, Differential regulation of extracellular matrix proteoglycan (PG) gene expression. Transforming growth factor-beta 1 up-regulates biglycan (PGI), and versican (large fibroblast PG) but down-regulates decorin (PGII) mRNA levels in human fibroblasts in culture. Journal of Biological Chemistry. ,vol. 266, pp. 10608- 10615 ,(1991) , 10.1016/S0021-9258(18)99267-7
Y. Takeuchi, Y. Kodama, T. Matsumoto, Bone matrix decorin binds transforming growth factor-beta and enhances its bioactivity. Journal of Biological Chemistry. ,vol. 269, pp. 32634- 32638 ,(1994) , 10.1016/S0021-9258(18)31681-8
Erkki I. Ruoslahti, Wayne A. Border, Inhibiting transforming growth factor .beta. to prevent accumulation of extracellular matrix ,(1992)
Fernando López-Casillas, Sela Cheifetz, Jacqueline Doody, Janet L. Andres, William S. Lane, Joan Massague, Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-β receptor system Cell. ,vol. 67, pp. 785- 795 ,(1991) , 10.1016/0092-8674(91)90073-8
T. Krusius, E. Ruoslahti, Primary structure of an extracellular matrix proteoglycan core protein deduced from cloned cDNA Proceedings of the National Academy of Sciences of the United States of America. ,vol. 83, pp. 7683- 7687 ,(1986) , 10.1073/PNAS.83.20.7683
R Morishita, G H Gibbons, K E Ellison, M Nakajima, H von der Leyen, L Zhang, Y Kaneda, T Ogihara, V J Dzau, Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. Journal of Clinical Investigation. ,vol. 93, pp. 1458- 1464 ,(1994) , 10.1172/JCI117123